Cell and Growth Factor-Loaded Keratin Hydrogels for Treatment of Volumetric Muscle Loss in a Mouse Model.
Wounds to the head, neck, and extremities have been estimated to account for ∼84% of reported combat injuries to military personnel. Volumetric muscle loss (VML), defined as skeletal muscle injuries in which tissue loss results in permanent functional impairment, is common among these injuries. The present standard of care entails the use of muscle flap transfers, which suffer from the need for additional surgery when using autografts or the risk of rejection when cadaveric grafts are used. Tissue engineering (TE) strategies for skeletal muscle repair have been investigated as a means to overcome current therapeutic limitations. In that regard, human hair-derived keratin (KN) biomaterials have been found to possess several favorable properties for use in TE applications and, as such, are a viable candidate for use in skeletal muscle repair. Herein, KN hydrogels with and without the addition of skeletal muscle progenitor cells (MPCs) and/or insulin-like growth factor 1 (IGF-1) and/or basic fibroblast growth factor (bFGF) were implanted in an established murine model of surgically induced VML injury to the latissimus dorsi (LD) muscle. Control treatments included surgery with no repair (NR) as well as implantation of bladder acellular matrix (BAM). In vitro muscle contraction force was evaluated at two months postsurgery through electrical stimulation of the explanted LD in an organ bath. Functional data indicated that implantation of KN+bFGF+IGF-1 (n = 8) enabled a greater recovery of contractile force than KN+bFGF (n = 8)***, KN+MPC (n = 8)**, KN+MPC+bFGF+IGF-1 (n = 8)**, BAM (n = 8)*, KN+IGF-1 (n = 8)*, KN+MPCs+bFGF (n = 9)*, or NR (n = 9)**, (*p < 0.05, **p < 0.01, ***p < 0.001). Consistent with the physiological findings, histological evaluation of retrieved tissue revealed much more extensive new muscle tissue formation in groups with greater functional recovery (e.g., KN+IGF-1+bFGF) when compared with observations in tissue from groups with lower functional recovery (i.e., BAM and NR). Taken together, these findings further indicate the general utility of KN biomaterials in TE and, moreover, specifically highlight their potential application in the treatment of VML injuries.
1 Fischell Department of Bioengineering, University of Maryland , College Park, Maryland.|2 Wake Forest Institute for Regenerative Medicine, Wake Forest University , Winston-Salem, North Carolina.
H B
HB
Baker
2 Wake Forest Institute for Regenerative Medicine, Wake Forest University , Winston-Salem, North Carolina.|3 Department of Biomedical Engineering, University of Virginia , Charlottesville, Virginia.
J A
JA
Passipieri
2 Wake Forest Institute for Regenerative Medicine, Wake Forest University , Winston-Salem, North Carolina.
Mevan
M
Siriwardane
4 KeraNetics, LLC , Winston-Salem, North Carolina.
Mary D
MD
Ellenburg
2 Wake Forest Institute for Regenerative Medicine, Wake Forest University , Winston-Salem, North Carolina.
Manasi
M
Vadhavkar
2 Wake Forest Institute for Regenerative Medicine, Wake Forest University , Winston-Salem, North Carolina.
Christopher R
CR
Bergman
5 Department of Chemical, Paper and Biomedical Engineering, Miami University , Oxford, Ohio.
Justin M
JM
Saul
4 KeraNetics, LLC , Winston-Salem, North Carolina.
Seth
S
Tomblyn
4 KeraNetics, LLC , Winston-Salem, North Carolina.
Luke
L
Burnett
2 Wake Forest Institute for Regenerative Medicine, Wake Forest University , Winston-Salem, North Carolina.|3 Department of Biomedical Engineering, University of Virginia , Charlottesville, Virginia.|6 Department of Orthopaedics, University of Virginia , Charlottesville, Virginia.
George J
GJ
Christ
D000818:Animals; D004337:Drug Carriers / Q000737:chemistry / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000737:chemistry / Q000494:pharmacology; D020100:Hydrogels / Q000737:chemistry / Q000494:pharmacology; D007334:Insulin-Like Growth Factor I / Q000737:chemistry / Q000494:pharmacology; D007633:Keratins / Q000737:chemistry / Q000494:pharmacology; D051379:Mice; D018482:Muscle, Skeletal / Q000293:injuries / Q000502:physiology; D012038:Regeneration / Q000187:drug effects*; D013552:Swine
D004337:Drug Carriers; D020100:Hydrogels; C519530:insulin-like growth factor-1, mouse; D016222:Fibroblast Growth Factor 2; D007334:Insulin-Like Growth Factor I; D007633:Keratins
FGF; IGF; keratin hydrogel; myogenesis; volumetric muscle loss